Me Therapeutics Holdings, Inc. · CSE:METX
Me Therapeutics — Investor Presentation (March 2025)
24 slides from Me Therapeutics's investor presentation, March 2025
Slide 1: Developing next generation therapeutics targeting immune suppression
Developing next generation therapeutics targeting immune suppression METX: CSE | FSE:Q9T
Slide 2: Disclaimer and forward-looking statements
This presentation provides an overview of ME Therapeutics Holdings Inc. (the “Company”). This presentation is solely intended to be a general overview and presentation of the Company. Nothing herein is to be construed as a solicitation or an offer to buy or sell any Company securities. The informati
Slide 3: Immuno-Oncology is a new area of clinical cancer research
Immuno-Oncology (IO) is a new area of clinical cancer research which has proven to be successful in treating previously untreatable cancers. IO drugs target the immune system rather than the cancer directly which allows them to be used to treat multiple cancer types with mostly manageable side effec
Slide 4: Myeloid Enhancement (ME) Therapeutics overview
Myeloid Enhancement (ME) Therapeutics is a preclinical stage biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called m
Slide 5: Cancer incidence and global IO market
> 18.1 million new cases of cancer > 9.5 million deaths worldwide* > $40.74 billion > Global IO market** > $396 billion > expected growth of global IO market** > 29.5 million new cancer cases > 16.4 million deaths* *cancer.gov ** Research and Markets Me Therapeutics | Investor Deck | 2025 5
Slide 6: Unlocking small fraction of the market = significant revenue potential
Our drug candidates target the immune system and not the cancer directly so they may be used in several cancer types. (310,720 estimated cases in the U.S. in 2024)* Current Immuno-Oncology (IO) drugs (Keytruda, Opdivo) = ~$150,000 per patient irrespective of cancer type (234,580 estimated cases in t
Slide 7: Improving current therapies by targeting multiple pathways
IMPROVING CURRENT THERAPIES BY TARGETING MULTIPLE PATHWAYS The promise for immunotherapy oncology • Current IO drugs (especially anti-PD1 checkpoint) have shown remarkable efficacy in some patients • Targets the immune system and not cancer directly • Market leading PD-1 checkpoint inhibitor Keytrud
Slide 8: Me Therapeutics | Investor Deck | 2025
Me Therapeutics | Investor Deck | 2025 8
Slide 9: Management and directors
| PhD, CEO, Director & Founder | PhD, Director • Former director of preclinical research • Honorary Assistant Professor at University at Qu Biologics of British Columbia • Industry and academic expertise in cancer, • Expertise in lymphocyte biology, autoimmunity and inflammation inflammation, and ca
Slide 10: Myeloid cells hinder cancer killing
MYELOID CELLS HINDER CANCER KILLING T cells • Most current IO drugs target cancer killing T cells Myeloid cells • Myeloid cells interfere with T cell function but can be targeted or reprogrammed to help eliminate tumor cells Tumor cells • Myeloid targeting can be effective in currently unresponsive
Slide 11: Molecule discovery to preclinical pipeline
MOLECULE DISCOVERY PRECLINICAL PHASE 1 Targeting mCRC and ovarian cancer Tumor-specific immune stimulation Tumor-specific suppression target In vivo CAR delivery targeting fibrosis Me Therapeutics | Investor Deck | 2025 11
Slide 12: Anti-G-CSF antibody program
• Anti-G-CSF antibody with picomolar affinity • Preliminary safety demonstrated in non- human primate studies • Surgical oncologists engaged and excited to initiate trial • GMP cell line development underway • Aiming for pre-IND meeting Q4 2025 • Exploring use to treat VEGF resistance in metastatic
Slide 13: Me Therapeutics | Investor Deck | 2025
Maniati et al. (2013). Nat Med PMID: 24013745 Me Therapeutics | Investor Deck | 2025 13
Slide 14: Targeting G-CSF could overcome several mechanisms of immune suppression
Targeting G-CSF has the potential to overcome several mechanisms of immune suppression Me Therapeutics | Investor Deck | 2025 14
Slide 15: Lead indications: metastatic colorectal and ovarian cancer
• Lead indications are metastatic colorectal (mCRC) and ovarian cancer → currently not treatable with IO • Clinical success of Summit Therapeutics PD-1/VEGF bi-specific (Ivonescimab) is creating a new category in IO • Ivonescimab improved survival vs Keytruda* ($29.5B** in sales in 2024) in clinical
Slide 16: Therapeutic mRNA to modify cancer or autoimmune responses
Designed to modify cancer or autoimmune responses Advantages: • Targeted Therapy –reprogram immune cells • Versatility- broad applicability in cancer and autoimmunity • Safety – minimal risk of genetic mutations • Speed of Development – ability to design and synthesize in days for quick testing • Lo
Slide 17: Development of mRNAs encoding immunomodulatory proteins, CARs, and nanobodies
Development of mRNAs encoding immunomodulatory proteins, CARs, and nanobodies Proprietary mRNA sequence design to control protein expression in vivo • Tissue-specific expression of chimeric mRNAs • Reduce systemic toxicity of key immunological targets Potential use of a single therapeutic mRNA for b
Slide 18: Partnered with NanoVation Therapeutics
Partnered with NanoVation Therapeutics (NTx) • Long circulating Lipid Nanoparticle (LNP) addresses a key challenge in mRNA delivery • Reduces liver uptake • Increases immune cell targeting in tumors • Novo Nordisk recently chose NTx as a partner for its metabolic disease program Layered patent prote
Slide 19: Exploring in-license of clinical stage asset
• Currently exploring in-license of clinical stage asset with upcoming clinical data readout • Potential to fill a large unmet clinical need in blood cancers • Current phase fully funded • Unique opportunity to gain access to clinical data before decision on potential registration trial • Strong par
Slide 20: Where we started
WHERE WE STARTED 1 3 5 7 Completed non- Partnered with Opened new lab Public listing on GLP toxicology NanoVation Tx on and office space Canadian Securities on h1B11-12 mRNA delivery Exchange Completed first in Initiated mRNA Completed proof of vivo testing of lead therapeutic concept therapeutic pr
Slide 21: Where we're headed
WHERE WE’RE HEADED 1 3 5 7 In vivo testing of Choose lead mRNA Financing for G-CSF tumor-specific candidate for clinical Phase 1 and mRNA therapeutic development programs mRNA Nasdaq or NYSE Listing GMP manufacture of Pre-IND meeting application h1B11-12 2 4 6 Me Therapeutics | Investor Deck | 2025
Slide 22: Using cutting-edge technology to develop next generation drug candidates
Using cutting-edge technology to develop next generation drug candidates against key immunological targets. Potential de-risked antibody-based Targeting key pathways in therapy for metastatic colorectal and myeloid cell biology to shift ovarian cancer the tumor microenvironment Tissue-specific expre
Slide 23: Upcoming development steps
• GMP cell line development and • Continue optimizing tissue-specific mRNA optimization of production underway sequences (Q3 2025 completion) • Proof of concept efficacy studies in mouse • GMP production run models of cancer and inflammation • IND-enabling studies in mCRC and • Platform technology f
Slide 24: Thank You
PhD - CEO and founder Address 177 Robson St. Vancouver, BC, Canada V6B0N3 Contact Info Thank You Email: salim@metherapeutics.com Website metherapeutics.com
Me Therapeutics Holdings — Investor Presentation (March 2025) on 6ix